News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Abbott Laboratories (ABT) Puts Former Solvay SA Flu-Vaccine Business Up for Sale; Could be Worth $619 Million


6/29/2010 6:59:19 AM

WSJ -- Abbott Laboratories is seeking a buyer for the flu-vaccine business it picked up in its recent purchase of Solvay SA's pharmaceutical unit, in a deal people familiar with the matter said could be worth €500 million ($619 million).

Read at Wall Street Journal
Read at Reuters
Read at Fox News
Read at Bioresearch Online
Read at News Release


comments powered by Disqus
Solvay SA
Abbott
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES